Baseline characteristics and previous treatments received for cold agglutinin disease
| Patient . | Additional hematologic condition . | Age at sutimlimab discontinuation . | Sex . | Thromboembolic events . | Disease duration [y] . | Previous treatment for CAD . |
|---|---|---|---|---|---|---|
| 1 | CAD after LPL | 75 | F | Venous thrombosis | 9 | Steroids, rituximab/bendamustine |
| 2 | n/a | 78 | F | Pulmonary embolism | 6 | Steroids, IV immunoglobulins, rituximab |
| 3 | mixed AIHA (MYD88-) | 81 | F | n/a | 15 | Steroids, rituximab, IV immunoglobulins |
| Patient . | Additional hematologic condition . | Age at sutimlimab discontinuation . | Sex . | Thromboembolic events . | Disease duration [y] . | Previous treatment for CAD . |
|---|---|---|---|---|---|---|
| 1 | CAD after LPL | 75 | F | Venous thrombosis | 9 | Steroids, rituximab/bendamustine |
| 2 | n/a | 78 | F | Pulmonary embolism | 6 | Steroids, IV immunoglobulins, rituximab |
| 3 | mixed AIHA (MYD88-) | 81 | F | n/a | 15 | Steroids, rituximab, IV immunoglobulins |
N/a, not applicable/available.